UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Pronged attack on tough stomach cancers
Disease control OngoingThis small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control a type of stomach cancer that cannot be removed by surgery. The goal is to see if this three-part approach is safe and can shrink or e…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Modified virus tested to attack tough esophageal cancers
Disease control OngoingThis early-stage study is testing the safety of adding a specially designed virus (OBP-301) to standard chemotherapy and radiation for patients with advanced esophageal or gastroesophageal cancer who are not candidates for surgery. The virus is meant to infect and kill cancer cel…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control OngoingThis study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…
Matched conditions: UNRESECTABLE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC